HR6624 forces a structural onshoring of U.S. synthetic biology IP and manufacturing away from PRC entities. Domestic pure-plays Ginkgo Bioworks ($DNA) and Twist Bioscience ($TWST) are direct beneficiaries, while large biopharma Amgen ($AMGN) and Regeneron ($REGN) face near-term capex pressure but reduced long-term IP risk. The bill advanced out of committee with bipartisan support and has an identical Senate companion bill, increasing passage probability.
TICKER INTELLIGENCE
$TWST
Company & Legislative Profile
$TWST is a publicly traded company in the Technology sector. This company operates across Technology and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 1 active Congressional signal mentioning $TWST, including 1 bill. The legislative sentiment is currently mixed, with both supportive and challenging policy signals in play.
$TWST is currently facing 1 active congressional signal tracked by HillSignal. With 0 bullish, 1 neutral, and 0 bearish signal, the average legislative impact score is 5.0/10. Key sectors affected include Technology, Healthcare and Manufacturing. Recent major catalysts include Biological Intellectual Property Protection Act of 2025. Below is the complete tracker of government activity affecting $TWSTβs market performance.
1
Total Signals
5.0/10
Avg Impact
0
Bullish Signals
0
Bearish Signals
Related Sectors
π On the Inside β Form 4 Activity in $TWST
Finn Patrick John sold $141K of $TWST
2,321 shares @ $60.76
Recent Congressional Signals for $TWST
Understanding These Signals
Get Full Access to $TWST Signals
Daily AI-analyzed alerts for Congressional activity affecting your portfolio.
Get Started β